acarbose
Selected indexed studies
- Acarbose enhances the efficacy of immunotherapy against solid tumours by modulating the gut microbiota. (Nat Metab, 2024) [PMID:39322747]
- Acarbose: an alpha-glucosidase inhibitor. (Am J Health Syst Pharm, 1996) [PMID:8893066]
- Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (Front Endocrinol (Lausanne), 2020) [PMID:32582019]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Acarbose improved survival for Apc(+/Min) mice. (2020) pubmed
- Acarbose enhances the efficacy of immunotherapy against solid tumours by modulating the gut microbiota. (2024) pubmed
- Acarbose: an alpha-glucosidase inhibitor. (1996) pubmed
- Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (2020) pubmed
- Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. (2008) pubmed
- The biosynthesis of acarbose and validamycin. (2001) pubmed
- The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis. (2021) pubmed
- [Biosynthesis and regulatory mechanism of acarbose and its structural analogs: a review]. (2022) pubmed
- Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases. (2024) pubmed
- Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance. (2019) pubmed